Dallas, United States
Spark Biomedical Inc is a pioneering company in the healthcare industry, specifically focused on non-invasive neurostimulation solutions. Founded in 2018, the company has made significant strides in developing innovative and evidence-based technologies to address diverse health challenges.
Their flagship product, the Sparrow Ascent, represents the second generation of their neurostimulation technology, building on the success of the Sparrow Therapy System. This FDA-cleared approach to treating opioid withdrawal symptoms has been groundbreaking in providing safe, comfortable, and drug-free solutions. At the core of Spark Biomedical is a commitment to redefining approaches to treatment and offering more to patients.
With a recent $318.88K grant investment from the National Institute on Drug Abuse (NIDA) in September 2024, Spark Biomedical is poised to further expand the impact of Sparrow Ascent and explore additional applications in addressing the challenges of opioid addiction.
As the company continues to innovate and demonstrate its potential to revolutionize the field of neurostimulation, it presents an exciting opportunity for investors and stakeholders in the healthcare, health and wellness, and medical devices industries.
-logo.jpg){kind=logo}
